AI assistant
BOSTON SCIENTIFIC CORP — Director's Dealing 2018
Nov 19, 2018
29821_dirs_2018-11-19_dac861af-526c-45c3-9eaf-fae5e9d61b11.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2018-11-16
Reporting Person: Nanavaty Maulik (SVP & Pres, Neuromodulation)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-11-16 | Common Stock | M | 23458.0000 | $8.3000 | Acquired | 256809.0000 | Direct |
| 2018-11-16 | Common Stock | S | 23458.0000 | $37.2771 | Disposed | 233351.0000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-11-16 | Stock Option (Right to Buy) | $8.3000 | M | 23458.0000 | Disposed | 2019-02-24 | Common Stock (23458.0000) | Direct |
Footnotes
F1: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
F2: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $37.27 to $37.30, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Grant to the reporting person of an option to purchase a specified number of common stock vesting in four equal annual installments beginning on February 24, 2010, the first anniversary of the date of grant.